Go Pro
NASDAQ:TYRA

Tyra Biosciences Q4 2024 Earnings Report

Tyra Biosciences logo
$24.94 -1.19 (-4.55%)
As of 08/28/2026 04:00 PM Eastern

Tyra Biosciences EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Tyra Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tyra Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Tyra Biosciences' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Tyra Biosciences Earnings Headlines

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet
3 Biggest Tech Billionaires Are ALL Backing This Potential $367 Trillion Tech
Elon Musk, Peter Thiel, and Sam Altman are backing a new AI use case discovered at MIT that has already identified potential treatments for dangerous diseases. McKinsey estimates this technology could be 500 times bigger than ChatGPT, while Nature projects it could add $367 trillion to the global economy.tc pixel
See More Tyra Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email.

About Tyra Biosciences

Tyra Biosciences (NASDAQ:TYRA) (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection.

Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.

View Tyra Biosciences Profile